Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”
Author:
Publisher
Springer Science and Business Media LLC
Subject
Dermatology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s40257-022-00694-z.pdf
Reference10 articles.
1. Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;90(1062):216–20. https://doi.org/10.1136/postgradmedj-2013-131994.
2. Savage K, Flood K, Porter M, Kimball A. TNF-α inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2019;10:204062231985164. https://doi.org/10.1177/2040622319851640.
3. Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989–94. https://doi.org/10.1111/jdv.13216.
4. Abdalla T, Lowes MA, Kaur N, Micheletti RG, Steinhart AH, Alavi A. Is there a role for therapeutic drug monitoring in patients with hidradenitis suppurativa on tumor necrosis factor-α inhibitors? Am J Clin Dermatol. 2021;22(2):139. https://doi.org/10.1007/s40257-020-00579-z.
5. Chen W, Chi C. Association of hidradenitis suppurativa with inflammatory bowel disease. JAMA Dermatol. 2019;155(9):1022–7. https://doi.org/10.1001/jamadermatol.2019.0891.
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17
2. Author’s Reply to Pestana et al. Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”;American Journal of Clinical Dermatology;2022-06-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3